MELOXICAM
| Brand name | QAMZOVA |
|---|---|
| Active ingredient | MELOXICAM |
| Strength | 30MG/ML (30MG/ML) |
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Modality | Small molecule |
| FDA approval | April 2025 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 12059423 | July 2040 | substance, product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.